Marburg, October 13, 2020, AGCT tested its novel EGFR prototype kit together with a German cancer research institute and HistogeneX, a global CRO laboratory supporting diagnostic and clinical studies in oncology with headquarters in Antwerp/Belgium. The results with non-clinical human DNA samples demonstrate cyberPCR’s high sensitivity with extreme wildtype DNA background and its superiority in a head-to-head comparison with today’s standard assays for real-time PCR and digital PCR platforms.
Dirk Loeffert, AGCT’s COO, who brings along almost 20 years of product development know-how from his former position at Qiagen, is very optimistic that the assay technology has the ability to outcompete existing methods and can be expanded to next generation sequencing approaches.
“Along with its superior performance as compared with other PCR based approaches, the great strength of AGCT’s assay technology is that it can be used on any real-time PCR cycler that is found in every molecular testing laboratory today. Furthermore, the technology also holds great promise to improve performance of other testing technology platforms such as digital PCR or NGS based testing.”
Further insights on AGCT’s prototype kit and the market relevance of the proprietary cyberPCR technology are provided in the Autumn Edition 2020 of the European Biotechnology Life Science and Industry Magazine.